JP2014527397A - 癌患者の化学療法に対する臨床応答を予測する方法 - Google Patents

癌患者の化学療法に対する臨床応答を予測する方法 Download PDF

Info

Publication number
JP2014527397A
JP2014527397A JP2014516320A JP2014516320A JP2014527397A JP 2014527397 A JP2014527397 A JP 2014527397A JP 2014516320 A JP2014516320 A JP 2014516320A JP 2014516320 A JP2014516320 A JP 2014516320A JP 2014527397 A JP2014527397 A JP 2014527397A
Authority
JP
Japan
Prior art keywords
chokα
cancer
patient
expression level
nsclc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014516320A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014527397A5 (https=
Inventor
フアン、カルロス、ラカル、サンファン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Traslational Cancer Drugs Pharma SL
Original Assignee
Traslational Cancer Drugs Pharma SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Traslational Cancer Drugs Pharma SL filed Critical Traslational Cancer Drugs Pharma SL
Publication of JP2014527397A publication Critical patent/JP2014527397A/ja
Publication of JP2014527397A5 publication Critical patent/JP2014527397A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014516320A 2011-06-20 2012-06-20 癌患者の化学療法に対する臨床応答を予測する方法 Pending JP2014527397A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP11382211.8 2011-06-20
EP11382211 2011-06-20
US201161507833P 2011-07-14 2011-07-14
US61/507,833 2011-07-14
EP11382294.4 2011-09-16
EP11382294 2011-09-16
PCT/EP2012/061790 WO2012175537A1 (en) 2011-06-20 2012-06-20 Method for predicting the clinical response to chemotherapy in a subject with cancer

Publications (2)

Publication Number Publication Date
JP2014527397A true JP2014527397A (ja) 2014-10-16
JP2014527397A5 JP2014527397A5 (https=) 2015-08-13

Family

ID=47422050

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014516320A Pending JP2014527397A (ja) 2011-06-20 2012-06-20 癌患者の化学療法に対する臨床応答を予測する方法

Country Status (11)

Country Link
US (1) US20150004252A1 (https=)
EP (1) EP2721174A1 (https=)
JP (1) JP2014527397A (https=)
KR (1) KR20140047664A (https=)
CN (1) CN103687964A (https=)
AU (1) AU2012274156A1 (https=)
BR (1) BR112013032857A2 (https=)
CA (1) CA2840129A1 (https=)
MX (1) MX2013015286A (https=)
RU (1) RU2014101492A (https=)
WO (1) WO2012175537A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017083739A1 (en) * 2015-11-13 2017-05-18 The Trustees Of Columbia University In The City Of New York A method for predicting a subject's response to valproic acid therapy
US20170305861A1 (en) * 2016-04-25 2017-10-26 Immunomet Therapeutics, Inc Heteroaryl compounds comprising nitrogen and use thereof
US10683292B2 (en) * 2016-07-25 2020-06-16 Nerviano Medical Sciences S.R.L. Purine and 3-deazapurine analogues as choline kinase inhibitors
WO2018177326A1 (en) * 2017-03-29 2018-10-04 Crown Bioscience Inc. (Taicang) System and method for determining karenitecin sensitivity on cancer
CN107050668B (zh) * 2017-06-09 2020-03-31 南京医科大学第一附属医院 基于云处理的放疗效果预测方法
EP3502700A1 (en) * 2017-12-21 2019-06-26 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Methods based on the detection of rad51 foci in tumor cells
CN116859058A (zh) * 2023-07-17 2023-10-10 上海中医药大学 一种基于NDR1-Myc互作抗结直肠癌活性分子筛选方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008535511A (ja) * 2005-04-13 2008-09-04 コンセホ スペリオール デ インベスティガシオネス シエンティフィカス 癌治療化合物のｉｎｖｉｔｒｏにおける同定方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
EP0491007B1 (en) 1989-09-08 1996-03-13 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ES2237332B1 (es) 2004-01-14 2006-11-01 Consejo Sup. Investig. Cientificas Derivados de piridinio y quinolinio.
GB0519405D0 (en) * 2005-09-23 2005-11-02 Univ Aberdeen Cancer therapy prognosis and target
RU2509809C2 (ru) * 2008-07-04 2014-03-20 Транслэшионал Кэнсэр Драгз Фарма, С.Л. Способы лечения и диагностики рака
US9896720B2 (en) 2008-09-10 2018-02-20 Rutgers, The State University Of New Jersey Imaging individual mRNA molecules using multiple singly labeled probes
US20100068302A1 (en) 2008-09-17 2010-03-18 Traslational Cancer Drugs Pharma, S.L. Methods and compositions for the treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008535511A (ja) * 2005-04-13 2008-09-04 コンセホ スペリオール デ インベスティガシオネス シエンティフィカス 癌治療化合物のｉｎｖｉｔｒｏにおける同定方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6016023739; ＰＬｏＳ　Ｃｏｍｐｕｔａｔｉｏｎａｌ　Ｂｉｏｌｏｇｙ Ｖｏｌ．７，Ｎｏ．３, 201103, ｅ１００１１１３ *
JPN6016023740; ＮＭＲ　Ｂｉｏｍｅｄ． ｖｏｌ．２３, 2010, ｐ．６３３-６４２ *
JPN6016023741; Ｃａｎｃｅｒ　Ｒｅｓｅａｒｃｈ , 20080501, ［ｏｎｌｉｎｅ］，［ｒｅｔｒｉｖｅｄ　ｏｎ　２０１６-０６-１６］ *
JPN6016023742; Ｌａｎｃｅｔ　Ｏｎｃｏｌ ｖｏｌ．８, 2007, ｐ．８８９-８９７ *

Also Published As

Publication number Publication date
WO2012175537A1 (en) 2012-12-27
CA2840129A1 (en) 2012-12-27
BR112013032857A2 (pt) 2017-01-24
EP2721174A1 (en) 2014-04-23
RU2014101492A (ru) 2015-07-27
KR20140047664A (ko) 2014-04-22
US20150004252A1 (en) 2015-01-01
CN103687964A (zh) 2014-03-26
AU2012274156A1 (en) 2014-01-23
MX2013015286A (es) 2014-09-25

Similar Documents

Publication Publication Date Title
EP2527460B1 (en) Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
JP5926487B2 (ja) ＥｒｂＢ療法に耐性である癌を治療するための方法
WO2008144345A2 (en) Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
CN103562406B (zh) 用于预测对艾日布林的反应的方法和组合物
US20110217309A1 (en) Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
HK1244847A1 (zh) 用於膀胱癌症的治疗，诊断和预後方法
JP2014527397A (ja) 癌患者の化学療法に対する臨床応答を予測する方法
US7998688B2 (en) Inhibition of EMT induction in tumor cells by anti-cancer agents
HK1221422A1 (zh) 诊断方法和用於治疗成胶质细胞瘤的组合物
JP2006500946A (ja) 精巣精上皮腫の診断方法
US9523691B2 (en) Use of the olfactomedin-4 protein (OLFM4) in colorectal cancer diagnosis
JP6297490B2 (ja) 診断マーカー
Lopez-Gines et al. Association between epidermal growth factor receptor amplification and ADP-ribosylation factor 1 methylation in human glioblastoma
CN114763574A (zh) Cdkn2a/2b缺失作为预测cdk4/6抑制剂在食管鳞癌中敏感性的生物标志物
EP2755030A1 (en) Prognostic marker for endometrial carcinoma
JP2018524614A (ja) 個別化された癌治療のための方法
US20120316187A1 (en) Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
EP3794353B1 (en) Spag5 as a biomarker for breast cancer treatment
JP2007522791A (ja) 結腸直腸癌を診断する方法
Pita¹ et al. CDK4 phosphorylation status and rational use for combining
Kamal et al. BRCA1 gene expression in breast cancer in relation to other prognostic markers in Egyptian women.
EP2034027A1 (en) Molecular markers to predict response to chemotherapy and EGFR family inhibiton by targeted strategies
CN114763573A (zh) Fgf19扩增作为预测fgfr抑制剂在食管鳞癌中敏感性的生物标志物及其潜在应用
Babyshkina et al. Non-Smad TGF-β signaling components are possible biomarkers of tamoxifen resistance
JP2010200625A (ja) 食道がんに対する放射線化学療法感受性マーカー

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150622

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160621

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170127